3 drug(s) with this reaction
2,017 total reports
Therapy Interrupted has been reported as an adverse reaction across 3 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 2,017 adverse event reports mention therapy interrupted in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with therapy interrupted, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have therapy interrupted listed in their FDA adverse event reports, sorted by report count:
In addition to therapy interrupted, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
3 drug(s) manufactured by Abbvie Inc have therapy interrupted listed in their FDA adverse event reports: UPADACITINIB, ATOGEPANT, GLECAPREVIR AND PIBRENTASVIR.
There are a combined 2,017 reports of therapy interrupted across 3 Abbvie Inc drug(s) in the FDA adverse event database.